Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines.

@article{Laskov2016MetforminIE,
  title={Metformin Increases E-cadherin in Tumors of Diabetic Patients With Endometrial Cancer and Suppresses Epithelial-Mesenchymal Transition in Endometrial Cancer Cell Lines.},
  author={Ido Laskov and Paul Abou-Nader and Oreekha Amin and Cooke Philip and M Beauchamp and Amber Yasmeen and Walter Henri Gotlieb},
  journal={International journal of gynecological cancer : official journal of the International Gynecological Cancer Society},
  year={2016},
  volume={26 7},
  pages={
          1213-21
        }
}
PURPOSE Epithelial-mesenchymal transition (EMT) is a critical process for cancer metastasis and recurrence. Metformin, an effective oral antidiabetic drug, has been associated with decreased cancer risk and mortality. In this pilot study, we started to evaluate the effect of metformin on EMT in vivo and in vitro in endometrial cancer (EC). METHODS Endometrial cancer cell lines and freshly isolated EC tumor specimens were used to assess EMT after metformin treatment. Cell lines were subjected… CONTINUE READING
1
Twitter Mention

Citations

Publications citing this paper.
SHOWING 1-9 OF 9 CITATIONS

Metformin as a Therapeutic Target in Endometrial Cancers

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Targeting Endometrial Cancer Stem Cell Activity with Metformin Is Inhibited by Patient-Derived Adipocyte-Secreted Factors

Sarah J Kitson, Matthew Rosser, +3 authors Emma J Crosbie
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND